PRWeek | 2021 Will Be Known As Year Medcomms M&A Went Into Overdrive

Nov 2021

Originally published by PRWeek on November 10, 2021, by James West.

Several large agency groups have taken on fresh private equity capital for the first time this year and many others have changed private equity ownership.

In each case, the thesis is simple: buy your way to growth and a full-service proposition.

Full-service medcomms spans everything from pre-clinical R&D strategy through medical affairs and market access work during clinical trials, and across to the marketing and creative work for brand launches (and relaunches) – and everything in between.

Within each bucket there are several niches in a sector known for being highly fragmented.

As the larger medcomms platforms scale and their valuations rise, this has corresponded to smaller agencies also experiencing a rise in valuations.

Deal structures now tend to be more attractive to sellers than in previous years, typically tying agency owners to the growth of the overall acquiring group and not solely the performance of the target company.

The days of the five-year earnout have largely disappeared and been replaced with more favourable win-win arrangements.

As bigger groups have greater firepower to acquire, sellers continue to sell.

The 10 most active medcomms acquirers have bought 19 companies so far in 2021, with many others being acquired by other medcomms agencies or non-healthcare buyers.

The trend from 2021 is that private equity-backed acquirers are accelerating the pace of M&A across Europe and the US, in particular.

Why are we experiencing heightened activity?

The pharma medcomms market is one of the most attractive sectors to operate in. It’s worth more than $10bn in 2021 and is growing 12 per cent annually, with medical affairs and publication work making up the largest budgets across the sub-sectors.

The focus on this sector compared with other industries remains high and I can’t see the spotlight moving off outsourced pharma services for years to come.

The tailwinds keeping the conveyor belt of M&A moving include:

  1. Fresh private equity capital in the sector.
  2. A continued focus on pharma and healthcare.
  3. Outsourcing trends within pharma increasing and staying elevated.
  4. The need for more complex data and analytical requirements which can only be performed by outsourced specialists.

This all drives the market forward and acts as an additional incentive for new agencies to have innovative services at the core of their business.

One major challenge for top acquirers will be retaining culture and spark, which is often a key reason agencies are so attractive to them. I’ve seen huge strides being made by acquirers to ensure culture remains in place post-acquisition.

Independent agency owners across the pharma and life science space will have a red-hot phone line as the private equity-backed platforms continue to grow through acquisition.



Meet Professionals with Complementary Expertise

Related Perspectives

Animal Health Players Pursue Vertical Integration as a Path to Growth

Animal health businesses that have established a strong presence within their area of expertise, may be considering where the next best path to growth lies. While cross-border expansion and consolidation… Read More

Cross-Border Deals: The Right Prescription for Animal Health

As the humanization of pets continues and pet lifespans grow longer, investment opportunities in animal health abound. While most animal health companies will first look for growth within their own… Read More

The Pharmaceutical Journal | Is Amazon Really a Threat to the UK Pharmacy Market?

Matthew Lee, Managing Director at Lincoln International joins the Pharmaceutical Journal deputy news editor, Carolyn Wickware, in a recent episode of The PJ Pod to share his thoughts on the… Read More

Whitepaper: 2021 Outlook for Value-Based Care and the Self-Insured Employer Marketplace

Numerous efforts to transition the U.S. healthcare system to a value-based care construct have been attempted during the past couple decades, including top-down initiatives such as accountable care organizations, with… Read More